Headquarter
Utrecht, The Netherlands 

Milestones
Founded: 2021
(Built and supported by Argobio)
Invested: 2025

Founders / CEO
Matthew Baker, CEO

Vertical
Biotech

Board Participation
Lola Buono, Board Observer

Website

Linkedin

Developer of a biotechnology platform designed to develop dual-targeted therapies through protein degradation. The company's platform focuses on the development of a biological approach for the treatment of tumors and neurological diseases with the help of surface removal targeting chimeric molecules, enabling medical professionals to get access to efficient and sustained degradation of target receptors.

Related news:

Laigo Bio raises €11.5M to transform targeted protein degradation in oncology and autoimmunity